Skip to Main Content

INFORMATION FOR

Latest News

  • “Complete Academic Physician” Dr. Karl Insogna Retires From Clinical Duties

    During his childhood in Wolcott, Conn., Karl Insogna’s parents instilled in him a few life lessons. Insogna, MD, FACP, Ensign Professor of Medicine (Endocrinology); director, Yale Bone Center; and associate director, Yale Center for X-Linked Hypophosphatemia; was taught to strive to leave the world a better place than you found it, and to do something to help others.

    Read more
  • Dr. Petrylak Reviews Results From KEYNOTE-921 in mCRPC

    Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

    Source: Targeted Oncology
    Read more
  • $20M Federal Grant Renewed for Yale Tobacco Center of Regulatory Science

    The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have renewed a $20 million grant for the Yale Tobacco Center of Regulatory Science (TCORS). The Yale center is led by co-directors Suchitra Krishnan-Sarin, PhD, Albert E. Kent Professor of Psychiatry; and Stephanie O’Malley, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry.

    Read more
  • Radioligand Therapy Improves PFS and Responses in SSTR+ Grade 2/3 GEP-NETs

    The use of lutetium 177Lu dotatate (Lutathera) and high-dose long-acting octreotide as frontline treatment for patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) led to significant improvements in progression-free survival (PFS) compared with high-dose long-acting octreotide alone. "This would represent a new indication for first-line treatment of GEP-NETS. In addition, this would represent the first theranostic agent FDA approved for use in the 1st line setting," said Kunz, associate professor of Internal Medicine (Medical Oncology); director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; chief, GI Medical Oncology; vice chief, Diversity, Equity, and Inclusion, Medical Oncology.

    Source: Targeted Oncology
    Read more